Abstract
Receptor for advanced glycation end products (RAGE) is expressed in a range of cell types such as endothelial cells, smooth muscle cells, mesangial cells, mononuclear phagocytes and certain neurons. It is a multi-ligand receptor and a member of the immunoglobulin superfamily of cell surface molecules. Its repertoire of ligands includes advanced glycation end products (AGEs), amyloid fibrils, amphoterin and S100/calgranulins. This variety of ligands allows RAGE to be implicated in a wide spectrum of pathological conditions such as diabetes and its complications, Alzheimers disease, cancer and inflammation. Additionally, genetic polymorphisms in the RAGE gene may have impact on the functional activity of the receptor. It becomes obvious that RAGE pathway is a complicated one and the question of whether blockade of RAGE is a feasible and safe strategy for the prevention/treatment of chronic diseases is gradually gaining the attention of the pharmaceutical community. In this review the biology of RAGE and the triggered signaling cascades involved in health and disease will be presented. Additionally, its potential as an attractive pharmacotherapeutic target will be explored by pointing out the pharmacotherapeutic agents that have been developed for RAGE blockade.
Keywords: RAGE, AGEs, S100 proteins, amphoterin, amyloid fibrils, chronic diseases, homeostasis, ligand-RAGE inhibition/blockade
Current Medicinal Chemistry
Title: RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Volume: 17 Issue: 21
Author(s): P. Alexiou, M. Chatzopoulou, K. Pegklidou and V.J. Demopoulos
Affiliation:
Keywords: RAGE, AGEs, S100 proteins, amphoterin, amyloid fibrils, chronic diseases, homeostasis, ligand-RAGE inhibition/blockade
Abstract: Receptor for advanced glycation end products (RAGE) is expressed in a range of cell types such as endothelial cells, smooth muscle cells, mesangial cells, mononuclear phagocytes and certain neurons. It is a multi-ligand receptor and a member of the immunoglobulin superfamily of cell surface molecules. Its repertoire of ligands includes advanced glycation end products (AGEs), amyloid fibrils, amphoterin and S100/calgranulins. This variety of ligands allows RAGE to be implicated in a wide spectrum of pathological conditions such as diabetes and its complications, Alzheimers disease, cancer and inflammation. Additionally, genetic polymorphisms in the RAGE gene may have impact on the functional activity of the receptor. It becomes obvious that RAGE pathway is a complicated one and the question of whether blockade of RAGE is a feasible and safe strategy for the prevention/treatment of chronic diseases is gradually gaining the attention of the pharmaceutical community. In this review the biology of RAGE and the triggered signaling cascades involved in health and disease will be presented. Additionally, its potential as an attractive pharmacotherapeutic target will be explored by pointing out the pharmacotherapeutic agents that have been developed for RAGE blockade.
Export Options
About this article
Cite this article as:
Alexiou P., Chatzopoulou M., Pegklidou K. and Demopoulos V.J., RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease, Current Medicinal Chemistry 2010; 17 (21) . https://dx.doi.org/10.2174/092986710791331086
DOI https://dx.doi.org/10.2174/092986710791331086 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals Assessment of Cardiac Sympathetic Innervation in Heart Failure and Lethal Arrhythmias: Therapeutic and Prognostic Implications
Current Cardiology Reviews Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry